NutriSystem (NTRI) Adopts Multi-Brand Strategy for 2018

NutriSystem Inc. NTRI has adopted a multi-brand strategy for Diet Season 2018, offering a series of healthy-structured weight loss options. These include NutriSystem for 2018 and South Beach Diet for 2018.

NutriSystem for 2018

It comprises two sub plans — NutriSystem Turbo13 and NutriSystem Turbo for Men.

The NutriSystem Turbo13 plan is a quick start weight loss plan. It includes Turbo TakeOff, a one-week jumpstart with specially designed foods, all-new NutriCurb bars, bestselling Turbo Shakes and the new TurboBoosters.

NutriSystem Inc Price

NutriSystem Inc Price | NutriSystem Inc Quote

NutriSystem Turbo for Men program includes new Nutri-Pro shakes containing 20 grams of proteins along with increased snacking options. With its intake, men can lose up to 15 lbs and 7 inches in the first month.

South Beach Diet for 2018

South Beach Diet is a structured weight-loss plan, which offers a high-protein, low-carb, low-sugar approach in diet. It is a three-phased low carb approach, designed to burn fat, change metabolism and stimulate energy.
According to NutriSystem, the low-sugar and low-carb approach of South Beach has boosted its demand. Launched earlier this year, South Beach contributed $5 million to revenues in the third quarter.

The 2018 campaign will be carried out with the help of the company’s brand ambassadors, social influencers and customer success stories and integrated across television, digital and social media channels.

Market Trends in Weight-Loss Industry

Per a research done by Markets and Markets, the weight loss and weight management market is estimated to reach $245.51 billion by 2022 at a CAGR of 6.9%. The growth of this market is primarily attributed to the growing rate of obesity and increasing incidence of lifestyle diseases.

Looking at this data, we are optimistic on NutriSystem’s 2018 plans. The company expects its customized solutions, which can be ordered online, to witness significant customer adoption.

Share Price Performance

Over the last one year, NutriSystem has outperformed the broader industry . The company has gained 49.5% in this period compared with the broader industry’s gain of 27.3%.

Zacks Rank & Key Picks

NutriSystem carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the industry are Akari Therapeutics PLC. AKTX, Bio-Rad Laboratories, Inc. BIO and C.R. Bard Inc. BCR. While Akari Theraputics and Bio-Rad sport a Zacks Rank #1 (Strong Buy), C.R. Bard Inc. (BCR) holds a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Akari’s projected EPS growth rate for the next quarter is 88.89%. Interestingly, over the past three quarters, the company has surpassed the Zacks Consensus Estimate by an average of 88.6%.

Bio-Rad’s projected EPS growth rate for the next quarter is 140.65%. The stock has rallied roughly 32% in the last year.

C.R. Bard’s projected EPS growth rate for the next year is 9.15%. The stock has rallied roughly 49.9% in the last one year.

Today's Stocks from Zacks' Hottest Strategies

It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.

And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.

See Them Free>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Bio-Rad Laboratories, Inc. (BIO) : Free Stock Analysis Report
 
C.R. Bard, Inc. (BCR) : Free Stock Analysis Report
 
NutriSystem Inc (NTRI) : Free Stock Analysis Report
 
Akari Therapeutics PLC (AKTX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research